BI 1015550 is an oral PDE4 inhibitor that preferentially inhibits PDE4B, and is a candidate drug for the treatment of IPF and other progressive fibrosing ILDs. The gene discussed is PDE4A; the disease is idiopathic pulmonary fibrosis.